Pnc Financial Services Group, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Pnc Financial Services Group, Inc.

$156 Billion
Q3 2024

A detailed history of Pnc Financial Services Group, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 58,462 shares of APLS stock, worth $1.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,462

Previous 59,088 1.06%

Holding current value

$1.94 Million

Previous $2.27 Million 25.6%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$28.84 - $41.15 $18,053 - $25,759	-626 Reduced 1.06%	58,462 $1.69 Million
Q2 2024 Aug 09, 2024	BUY	$38.07 - $59.71 $18,197 - $28,541	478 Added 0.82%	59,088 $2.27 Million
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $3.39 Million - $4.43 Million	-61,175 Reduced 51.07%	58,610 $3.45 Million
Q4 2023 Feb 09, 2024	BUY	$37.14 - $64.82 $1,671 - $2,916	45 Added 0.04%	119,785 $7.17 Million
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $61,750 - $232,953	-2,611 Reduced 2.13%	119,740 $4.55 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $4.67 Million - $5.68 Million	60,886 Added 99.06%	122,351 $11.1 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $23,760 - $34,149	510 Added 0.84%	61,465 $4.05 Million
Q4 2022 Feb 10, 2023	BUY	$43.24 - $61.04 $130,109 - $183,669	3,009 Added 5.19%	60,955 $3.15 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $8,683 - $13,514	194 Added 0.34%	57,946 $3.96 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $1,858 - $3,138	53 Added 0.09%	57,752 $2.61 Million
Q1 2022 May 12, 2022	BUY	$35.46 - $54.12 $1.59 Million - $2.42 Million	44,751 Added 345.62%	57,699 $2.93 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $211,798 - $338,712	6,890 Added 113.73%	12,948 $612,000
Q3 2021 Nov 05, 2021	BUY	$31.4 - $69.84 $3,454 - $7,682	110 Added 1.85%	6,058 $199,000
Q3 2020 Nov 06, 2020	BUY	$25.89 - $33.65 $24,336 - $31,631	940 Added 18.77%	5,948 $179,000
Q2 2020 Aug 07, 2020	BUY	$24.8 - $38.49 $198 - $307	8 Added 0.16%	5,008 $163,000
Q4 2019 Feb 07, 2020	SELL	$22.1 - $30.8 $83,096 - $115,808	-3,760 Reduced 42.92%	5,000 $153,000
Q3 2019 Nov 08, 2019	SELL	$24.09 - $32.18 $26,499 - $35,398	-1,100 Reduced 11.16%	8,760 $211,000
Q2 2019 Aug 09, 2019	SELL	$18.0 - $25.34 $77,040 - $108,455	-4,280 Reduced 30.27%	9,860 $0
Q1 2019 May 10, 2019	BUY	$12.81 - $19.82 $60,975 - $94,343	4,760 Added 50.75%	14,140 $0
Q4 2018 Feb 08, 2019	BUY	$11.47 - $18.71 $27,986 - $45,652	2,440 Added 35.16%	9,380 $123,000
Q3 2018 Nov 09, 2018	SELL	$16.57 - $21.03 $7,290 - $9,253	-440 Reduced 5.96%	6,940 $0
Q2 2018 Aug 10, 2018	BUY	$19.63 - $30.0 $144,869 - $221,400	7,380 New	7,380 $0

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Account

Pnc Financial Services Group, Inc. Apellis Pharmaceuticals, Inc. Transaction History